Amelia E B Moore, James E Burns, Deirdre Sally, Ana Milinkovic, Georgios Krokos, Joemon John, Christopher Rookyard, Alessandro Borca, Erica R M Pool, Anna Tostevin, Alyss Harman, Dwight S Dulnoan, Richard Gilson, Alejandro Arenas-Pinto, Gary J R Cook, John Saunders, David Dunn, Glen M Blake, Sarah L Pett
OBJECTIVE: Bone loss in people with HIV (PWH) is poorly understood. Switching tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has yielded bone mineral density (BMD) increases. PETRAM (NCT#:03405012) investigated whether BMD and bone turnover changes correlate. DESIGN: Open-label, randomized controlled trial. SETTING: Single-site, outpatient, secondary care. PARTICIPANTS: Nonosteoporotic, virologically suppressed, cis-male PWH taking TDF/emtricitabine (FTC)/rilpivirine (RPV) for more than 24 weeks...
March 15, 2024: AIDS